Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial
Pieter F van der Meer, Paula F Ypma, Nan van Geloven, Joost A van Hilten, Rinie J van Wordragen-Vlaswinkel, Okke Eissen, Jaap J Zwaginga, Michael Trus, Erik A M Beckers, Peter Te Boekhorst, Alan Tinmouth, Yulia Lin, Cyrus Hsia, David Lee, Philip J Norris, Raymond P Goodrich, Anneke Brand, Tor Hervig, Nancy M Heddle, Johanna G van der Bom, Jean-Louis H Kerkhoffs, Pieter F van der Meer, Paula F Ypma, Nan van Geloven, Joost A van Hilten, Rinie J van Wordragen-Vlaswinkel, Okke Eissen, Jaap J Zwaginga, Michael Trus, Erik A M Beckers, Peter Te Boekhorst, Alan Tinmouth, Yulia Lin, Cyrus Hsia, David Lee, Philip J Norris, Raymond P Goodrich, Anneke Brand, Tor Hervig, Nancy M Heddle, Johanna G van der Bom, Jean-Louis H Kerkhoffs
Abstract
Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections. However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We conducted a randomized noninferiority trial comparing the efficacy of pathogen-inactivated platelets using riboflavin and UV B illumination technology (intervention) compared with standard plasma-stored platelets (control) for the prevention of bleeding in patients with hematologic malignancies and thrombocytopenia. The primary outcome parameter was the proportion of transfusion-treatment periods in which the patient had grade 2 or higher bleeding, as defined by World Health Organization criteria. Between November 2010 and April 2016, 469 unique patients were randomized to 567 transfusion-treatment periods (283 in the control arm, 284 in the intervention arm). There was a 3% absolute difference in grade 2 or higher bleeding in the intention-to-treat analysis: 51% of the transfusion-treatment periods in the control arm and 54% in the intervention arm (95% confidence interval [CI], -6 to 11; P = .012 for noninferiority). However, in the per-protocol analysis, the difference in grade 2 or higher bleeding was 8%: 44% in the control arm and 52% in the intervention arm (95% CI -2 to 18; P = .19 for noninferiority). Transfusion increment parameters were ∼50% lower in the intervention arm. There was no difference in the proportion of patients developing HLA class I alloantibodies. In conclusion, the noninferiority criterion for pathogen-inactivated platelets was met in the intention-to-treat analysis. This finding was not demonstrated in the per-protocol analysis. This trial was registered at The Netherlands National Trial Registry as #NTR2106 and at www.clinicaltrials.gov as #NCT02783313.
© 2018 by The American Society of Hematology.
Source: PubMed